Article Tools
Hematologic Malignancies
Article Tools
Overexpression of the ETS-Related Gene, ERG, Predicts a Worse Outcome in Acute Myeloid Leukemia With Normal Karyotype: A Cancer and Leukemia Group B Study
Abstract
To test the prognostic significance of ETS-related gene (ERG) expression in cytogenetically normal primary acute myeloid leukemia (AML).
Pretreatment blood samples from 84 cytogenetically normal AML patients aged less than 60 years, who were characterized for BAALC expression, FLT3 internal tandem duplication (ITD), and MLL partial tandem duplication (PTD) and uniformly treated on Cancer and Leukemia Group B 9621 protocol, were analyzed for ERG expression by real-time reverse transcriptase polymerase chain reaction. Patients were divided into quartiles according to ERG levels and were compared for clinical outcome. High-density oligonucleotide arrays were used to identify genes differentially expressed between high and low ERG expressers.
With a median follow-up of 5.7 years, patients with the upper 25% of ERG expression values had a worse cumulative incidence of relapse (CIR; P < .001) and overall survival (OS; P = .011) than the remaining patients. In a multivariable analysis, high ERG expression (P < .001) and the presence of MLL PTD (P = .027) predicted worse CIR. With regard to OS, an interaction was observed between expression of ERG and BAALC (P = .013), with ERG overexpression predicting shorter survival only in low BAALC expressers (P = .002). ERG overexpression was an independent prognostic factor even when the unfavorable group of FLT3 ITD patients lacking an FLT3 wild-type allele was included. High ERG expression was associated with upregulation of 112 expressed-sequenced tags and named genes, many of which are involved in cell proliferation, differentiation, and apoptosis.
Cytogenetic abnormalities detected at diagnosis have long been recognized as predictors for clinical outcome in acute myeloid leukemia (AML).1 However, the largest cytogenetic subset of adult AML, approximately 45%, consists of patients with a normal karyotype.1 In large studies of the clinical significance of cytogenetics in AML, these patients have been categorized in an intermediate-risk group, with 5-year survival rates varying between 24% and 42%.2-5 The difference in clinical outcome likely reflects molecular heterogeneity of this cytogenetic subset whose prognosis is influenced by submicroscopic gene mutations or overexpression.6 The adverse prognostic impact of the partial tandem duplication (PTD) of MLL, internal tandem duplication (ITD) of FLT3, and overexpression of BAALC in karyotypically normal AML is now established,7-17 as is the favorable prognostic significance of CEBPA gene mutations.17,18 However, it is likely that, in addition to the aforementioned genetic abnormalities, others will be found to impact on the clinical outcome of cytogenetically normal AML. Given that intensive treatments such as allogeneic stem-cell transplantation (SCT), although potentially curative in patients with poor prognosis AML, are associated with high treatment-related mortality, novel molecular markers will likely be valuable to stratify karyotypically normal AML patients to risk-adapted therapies. Furthermore, because these markers are mutated or overexpressed genes encoding proteins with potentially pivotal roles in leukemogenesis, they could also serve as molecular targets for novel therapeutic approaches.19
We have recently shown that ETS-related gene (ERG), which is located at chromosome band 21q22, is frequently overexpressed in AML patients with complex karyotypes and cryptic amplification of chromosome 21.20 ERG and other members of the ETS family are downstream effectors of mitogenic signaling transduction pathways and are involved in key steps regulating cell proliferation, differentiation, and apoptosis.21-23 Although ERG rearrangements have been found in AML24 and Ewing sarcoma25 and its overexpression has been observed in prostate cancer,26 little is known regarding how ERG contributes to malignant transformation.27 In our previous report,20 high ERG expression was not always associated with genomic amplification, thereby leaving ERG overexpression mechanistically unexplained. Nevertheless, the recurrent presence of ERG overexpression in AML with complex karyotypes, a prognostically unfavorable subgroup, suggests that ERG overexpression might not only be a nonrandom event in myeloid leukemogenesis, but also might contribute to an aggressive malignant phenotype.
To test this hypothesis, we analyzed karyotypically normal AML patients who were uniformly treated on the Cancer and Leukemia Group B (CALGB) 9621 protocol.28 We show that the level of ERG expression varies among patients and that ERG overexpression constitutes an adverse prognostic factor in cytogenetically normal AML.
ERG expression was analyzed in 84 adults aged less than 60 years with primary, untreated AML and normal cytogenetics confirmed by central morphologic and karyotype reviews. Eligible patients were enrolled onto the treatment trial CALGB 9621,28 the prospective cytogenetic study CALGB 8461,29 and the molecular study of BAALC expression (CALGB 9665).15 Written institutional review board–approved informed consent was obtained from all patients.
Pretreatment cytogenetic analyses of bone marrow (BM) were performed as previously described.4,30At least 20 metaphases were analyzed, and the karyotype was normal in each case. Pretreatment MLL PTD and FLT3 ITD status and BAALC levels were also determined centrally for each patient, as described previously.7,10,15
Patients received induction chemotherapy with cytarabine, daunorubicin, and etoposide with valspodar (PSC-833) or without valspodar.28 On achievement of complete remission (CR), patients received high-dose etoposide and cytarabine for stem-cell mobilization followed by myeloablative treatment with busulfan and etoposide supported by autologous peripheral-blood SCT (APBSCT). Patients unable to receive APBSCT received two additional cycles of high-dose cytarabine. After consolidation, patients received maintenance with interleukin-2.
ERG expression was measured in blood for consistency with our previous analysis of the same patients characterized for BAALC expression.15 Mononuclear cells from pretreatment blood were enriched by Ficoll-Hypaque gradient and cryopreserved in liquid nitrogen. Samples were chosen based on the availability of procured material with adequate RNA quality in the CALGB Leukemia Tissue Bank. Total RNA was extracted using Trizol reagent (Invitrogen, Carlsbad, CA). cDNA synthesis and the real-time amplification reactions were performed as previously reported.15
The comparative cycle threshold (CT) method was used to determine the relative expression levels of ERG to GPI, the internal control, in patients previously included in the BAALC expression study.15 Of the original 86 patients, 84 were analyzed for ERG/GPI levels calculated using the mean of ΔCT from two replicates and expressed as 2μ(ΔCT). The results of real-time reverse transcriptase polymerase chain reaction (RT-PCR) were correlated with clinical end points.
To assess the impact of ERG levels on clinical outcome, we also adopted an alternative approach. Absolute ERG copy numbers were measured and normalized to the copy numbers of ABL, which was a different internal control validated by multicenter studies,31,32 using standard curves constructed as reported previously.33 We analyzed 73 samples comprising 48 samples from patients included in the set evaluated for ERG/GPI levels and for whom leftover material was available and 25 samples from additional, karyotypically normal AML patients enrolled onto CALGB 9621. Importantly, eight of the latter patients had the unfavorable FLT3ITD/− genotype,10 the presence of which was a reason for exclusion from the previous BAALC study.15
Positive and negative controls were included in all assays. The reproducibility of the real-time RT-PCR assays was similar to what we reported previously.15
Suitable RNA samples from 61 patients characterized for ERG/ABL expression were analyzed using Affymetrix U133 plus 2.0 GeneChips (Affymetrix, Santa Clara, CA). From 8 μg of total RNA, double-stranded cDNA was prepared (Invitrogen) with the use of the T7-Oligo(dT) primer (Affymetrix). In vitro transcription was performed with the BioArray HighYield RNA Transcript Labeling Kit (T7) (Enzo Life Science, Farmingdale, NY). Twenty micrograms of fragmented, biotinylated RNA was hybridized to the U133 plus 2.0 GeneChip for 16 hours at 45°C. Scanned images were converted to CEL files using GCOS software (Affymetrix).
CR was defined as recovery of morphologically normal BM and blood counts (ie, neutrophils ≥ 1,500/μL and platelets ≥ 100,000/μL) and no circulating leukemic blasts or evidence of extramedullary leukemia. Relapse was defined by more than 5% blasts in marrow aspirates or the development of extramedullary leukemia in patients with previously documented CR, according to National Cancer Institute criteria.34
Cumulative incidence of relapse (CIR) was measured from the CR date to date of relapse, death, or date last known alive, where death in CR was considered a competing risk. Disease-free survival (DFS) was measured from the CR date until date of relapse or death (regardless of cause), censoring for patients alive at last follow-up. DFS was used only for the 73 patients analyzed for ERG/ABL because none of them died in CR, and therefore, DFS reflected the actual relapse risk. Overall survival (OS) was measured from the date the patient was enrolled onto the study until the date of death or date last known alive.
The main objective was to evaluate the impact of ERG expression on clinical outcome. A set of 84 patients was initially divided into quartile (Q) groups according to levels of ERG/GPI expression and subsequently dichotomized into groups including the three lower Qs (Q1, Q2, and Q3) and the upper Q (Q4) of ERG/GPI values. Q4 was chosen for the cut point because the relapse risk was significantly different for the Q4 group compared with the Q1 (P = .024), Q2 (P = .002), and Q3 (P = .009) groups. Similarly, the 73 patients characterized for ERG/ABL copy numbers in blood were dichotomized into Q1-3 and Q4 groups based on the number of normalized ERG copies. Pretreatment clinical features were compared between Q1-3 and Q4 groups using the Fisher's two-sided exact and Wilcoxon rank sum tests for categoric and continuous variables, respectively.
Estimated probabilities of OS and DFS were calculated using the Kaplan-Meier method, and the log-rank test evaluated differences between survival distributions. Estimates of CIR were calculated, and Gray's k-sample test35 evaluated differences in relapse rates. Proportional hazards models were constructed for OS and DFS,36 whereas a multivariable model using Gray's method was constructed for CIR37 using a limited backwards selection procedure. Variables remaining in the final models were significant at α = .05. Adjusted survival curves were generated from the proportional hazards and Gray models using average covariate values.
For microarray data analysis, normalization and model-based expression index (MBEI) computations were performed using dChip version 1.3 (Harvard University, Cambridge, MA).38-40 Only the perfect match probes were used in the computation of MBEIs, whereas mismatch probes were ignored. Log[MBEI] values were calculated and then exported to BRB-ArrayTools v3.2.3 (National Cancer Institute, Bethesda, MD) for further analysis. Probe sets with a variance in log[MBEI] values above the 80th percentile were retained for further analyses (n = 10,935). A comparison of gene expression between Q1-3 and Q4 was performed by two-sample t tests using α = .001 as the significance level, which would result in approximately 11 expected false discoveries assuming no gene expression differences between the two groups. A permutation test was performed to validate the results of the parametric test. All analyses were performed by the CALGB Statistical Center.
No significant differences were observed in most pretreatment clinical characteristics between patients with the lowest 75% (Q1-3) and highest 25% (Q4) of ERG expression values. The two groups differed for BAALC expression levels (P = .042), circulating (P = .045) and BM (P = .056) blast percentages, gum hypertrophy (P = .060), and French-American-British subgroup distribution (P = .023; Table 1).
The CR rate was 81%, with no significant difference between patients in Q4 and Q1-3 (P = .532; Table 2). With a median follow-up of 5.7 years (range, 4.4 to 7.4 years), patients in Q4 had a worse CIR than patients in Q1-3 (P < .001; Fig 1A). The estimated 5-year relapse rate for Q4 patients was 81% compared with 33% for Q1-3 patients (Table 2). Furthermore, the OS was different between the two groups (P = .011; Fig 1B). Patients in Q4 had a median survival time of 1.2 years and an estimated 5-year survival rate of 19%; in contrast, median survival time for Q1-3 patients has not been reached, and their estimated 5-year survival rate was 51% (Table 2). When analysis was restricted to the set of patients who achieved CR and received APBSCT as a prescribed consolidation treatment (n = 49), ERG remained a significant adverse factor for outcome (data not shown).
On multivariable analysis, high ERG expression (ie, Q4) adversely impacted CIR (P < .001), as did the presence of MLL PTD (P = .027; Table 3, Fig 2A). Patients in Q4 had an estimated relapse risk almost four times higher than patients in Q1-3. For OS, an interaction between expression of ERG and BAALC (P = .013) was observed (Table 3). For low BAALC levels, patients in Q4 had a shorter survival than patients in Q1-3 (P = .002; Fig 2B, Table 3). However, the adverse impact of high ERG expression on OS was not observed in patients with high BAALC expression (P = .922; Fig 2C, Table 3). The only patients who maintained a long-term survival rate greater than 50% were patients with lower expression of both ERG and BAALC. Additionally, worse survival was associated with higher log[WBC] (P = .012; Table 3). Although Q4 patients had a higher percentage of circulating blasts at diagnosis (Table 1), this factor did not impact significantly on clinical outcome and, consequently, was not included in the multivariable models.
Similar results were obtained when we used a second analytic strategy uing specific standard curves to measure ERG copy numbers normalized to ABL.32,33 To explore whether ERG expression predicts clinical outcome independently from other major unfavorable prognostic markers, we included samples with the most unfavorable FLT3 genotype, FLT3ITD/−. Normalized ERG copies ranged from 0.4 to 735.9 (median, 17.9 copies). Patients with the lowest 75% (Q1-3; n = 55) of ERG copies (median, 11.0 copies; range, 0.4 to 35.1 copies) were compared with patients with the highest 25% (Q4; n = 18) of ERG copies (median, 62.2 copies; range, 37.5 to 735.9 copies). There were no significant differences in FLT3 genotype distribution, which included wild-type FLT3 (FLT3WT/WT), FLT3 ITD expressing the wild-type allele (FLT3ITD/WT), and FLT3 ITD lacking the wild-type allele (FLT3ITD/−; P = .644). Patients in Q4 had a worse DFS (P = .092) and OS (P = .003) than patients in Q1-3, with an estimated 5-year DFS of 25% (95% CI, 6% to 50%) v 53% (95% CI, 38% to 66%), respectively, and OS of 22% (95% CI, 7% to 43%) v 54% (95% CI, 40% to 67%), respectively. When the analysis was restricted to the subset of 25 patients not analyzed for ERG/GPI, ERG overexpression remained a significant adverse predictor for both OS and DFS (data not shown).
In a multivariable model, high ERG copy number (ie, Q4; P = .023; Fig 3A) and FLT3 ITD (P < .001) independently predicted worse DFS. The estimated relapse risk for Q4 patients was more than twice the risk for Q1-3 patients (hazard ratio [HR] = 2.55; 95% CI, 1.14 to 5.69). Patients with FLT3ITD/− and FLT3ITD/WT had an estimated relapse risk eight times (HR = 8.37; 95% CI, 2.91 to 24.08) and three times (HR = 3.23; 95% CI, 1.44 to 7.23) the risk of patients with FLT3WT/WT, respectively. In a multivariable model for OS, high ERG (HR = 3.05; 95% CI, 1.53 to 6.05; P = .002; Fig 3B), high log[WBC] (HR = 1.68; 95% CI, 1.14 to 2.46; P = .009), and FLT3 ITD (P = .002) predicted shorter survival. Patients with FLT3ITD/− and FLT3ITD/WT had six times (HR = 6.21; 95% CI, 2.42 to 15.93) and two times (HR = 2.09; 95% CI, 0.98 to 4.47), respectively, the estimated risk of dying compared with FLT3WT/WT patients.
Microarray gene expression profiling was conducted to assess whether ERG overexpression was associated with a specific signature suggestive of the gene's potential leukemogenic role. One hundred seventeen probes in the Affymetrix U133 plus 2.0 GeneChip were differentially expressed (P < .001) between the Q1-3 and Q4 groups, including 63 unique, named genes and 49 expressed-sequenced tags. Twenty-five probes corresponding to 14 named genes (Table 4) and eight expressed-sequenced tags had at least a two-fold difference in expression levels between the Q1-3 and Q4 groups (Fig 4). Supporting our real-time RT-PCR results, three probe sets for ERG were differentially expressed, with average expression 2.1 to 2.6 times higher in Q4 patients.
Of the 63 named genes overexpressed in Q4, functional characterization was available for 53. Twenty-three of the genes are involved in DNA and/or RNA binding and chromatin remodeling, including general transcription activators (ie, GTF2H2, FAM48A, TCF12, and GCN5L2) or repressors (CTBP2) and lineage-specific transcription regulators, such as BCL11A, which is involved in lymphoid cell development,41 and HEMGN, which is involved in myeloid differentiation.42-44 Other genes encode small GTPases, members of the RAS superfamily (RALA and RAB10) or their regulators (RABGAP1 and ARHGAP22), or proteins involved in membrane-receptor signaling pathways (GPR21, DPAGT1, PILRB, GPR89, and FRMD4B), including activators of small GTPases. Surprisingly, we found overexpression of three proapoptotic genes (PACAP, IKIP, and DAPK1); DAPK1 was recently reported to be silenced by methylation in AML.45 Finally, the following three genes with unknown function but linked to hereditary diseases were upregulated: ATXN2, which is mutated in autosomal-dominant spinocerebellar ataxia-2,46 SHANK3, which is involved in the 22q13 deletion syndrome,47 and OFD1, which is mutated in orofaciodigital syndrome I.48 To our knowledge, overexpression or mutations of these genes have hitherto not been reported in AML.
Although molecular mechanisms underlying diverse clinical outcome in cytogenetically normal AML are not fully understood, recent studies have identified several biomarkers correlated with prognosis.6-18 Here, we report for the first time that ERG overexpression predicted an increased relapse risk and short survival in AML patients with normal karyotype by both univariable and multivariable analyses. Despite a relatively small number of patients studied, our data support the addition of ERG overexpression to the emerging list of markers predictive for clinical outcome in cytogenetically normal AML.
With the number of prognostic markers growing, the relative contribution of each in predicting treatment outcome becomes important. In the current study, although high ERG levels correlated with an increased relapse risk regardless of the BAALC expression, a prognostic interaction between ERG and BAALC expression was observed for OS, with a shorter survival associated with high ERG levels only among patients with low BAALC expression. Likewise, interactions among prognostic markers, such as a greater prognostic importance of FLT3 ITD compared with BAALC overexpression and of BAALC overexpression compared with CEBPA mutations, have been reported previously.15,17,18 Because data on the impact of the concurrent presence of two or more molecular markers in cytogenetically normal AML are limited, further investigation of prognostic interactions is required by large prospective studies, with the goal of designing a prioritized, clinically relevant prognostic classification.
Although our data suggest that expression of ERG is useful for prognostic stratification of cytogenetically normal AML, the mechanism through which ERG overexpression contributes to myeloid leukemogenesis remains unknown. ERG is one of more than 30 members of the ETS gene family, most of which are downstream nuclear targets of signal transduction pathways regulating and promoting cell differentiation, proliferation, and tissue invasion.21,22,27 Rearrangement of ERG was initially discovered in Ewing sarcomas harboring t(21;22)(q22;q12), which at the molecular level fuses ERG with EWS.25 Other ETS family members also fuse with EWS in Ewing sarcomas.49-51 In AML carrying t(16;21)(p11;q22), ERG was found rearranged with FUS, linking ERG with myeloid leukemogenesis for the first time.24 Interestingly, like EWS, FUS is a member of the TET family of RNA-binding proteins,52 supporting the notion that gene rearrangements involving ETS members are often characterized by a TET-related transactivation domain at the N terminus and ETS DNA binding and protein-protein interaction domains at the C terminus. This structure likely increases the oncogenic activity of the resulting chimeric transcription factors by redirecting them to specific targets. Interestingly, a role for ERG in endothelial cell differentiation and angiogenesis was recently suggested.23,53
Our microarray gene expression profiling analysis, using a supervised analysis, identified a molecular signature for patients in the highest Q (Q4) of ERG expression. Many genes upregulated in Q4, including ERG, encode proteins functioning as transcription factors or involved in chromatin remodeling and RNA processing; others encode proteins regulating cell differentiation, proliferation, and apoptosis. Interestingly, the recently described HEMGN gene (also known as EDAG) was the most differentially expressed gene between the two groups. This gene reportedly regulates proliferation, differentiation, and apoptosis of hematopoietic cells and seems to be significantly overexpressed in refractory AML patients but not in patients with chemotherapy-sensitive disease.42-44
Because the molecular signature for the ERG overexpressers was defined by patients' clustering based on previously identified prognostic groups (ie, Q4 v Q1-3), it was not surprising that this gene profile was associated with a worse clinical outcome (data not shown). Obviously, for ERG expression to become a molecular marker used routinely for risk stratification in AML with normal cytogenetics, our data require confirmation in an independent, large patient cohort.
The Appendix is included in the full-text version of this article, available online at www.jco.org. It is not included in the PDF (via Adobe® Acrobat Reader®) version.
The authors indicated no potential conflicts of interest.
Fig 1. Clinical outcome of patients grouped by ETS-related gene (ERG) expression into quartile 4 (Q4), the uppermost quartile, and quartiles 1 to 3 (Q1-3), the lower quartiles. (A) Cumulative incidence of relapse. (B) Overall survival.
Fig 2. Predicted clinical outcome for the ETS-related gene (ERG) quartiles 1 to 3 (Q1-3) versus quartile 4 (Q4) groups. (A) Cumulative incidence of relapse. Curves are adjusted for MLL partial tandem duplication. (B and C) Overall survival for patients with (B) low and (C) high BAALC expression. Curves are adjusted for log[WBC] and BAALC. Results are based on 63 Q1-3 patients (36 with low and 27 with high BAALC expression) and 21 Q4 patients (six with low and 15 with high BAALC expression).
Fig 3. Predicted clinical outcome for patients grouped by ETS-related gene (ERG) copy number into the ERG quartiles 1 to 3 (Q1-3) and quartile 4 (Q4) groups. (A) Disease-free survival. Curves are adjusted for FLT3 genotypes (FLT3WT/WT v FLT3WT/ITD and FLT3WT/WT v FLT3ITD/−). (B) Overall survival. Curves are adjusted for log[WBC] and FLT3 genotypes.
Fig 4. Heat map of two-fold or greater differentially expressed genes between ETS-related gene (ERG) quartiles 1 to 3 (Q1-3) and quartile 4 (Q4). Columns represent samples, and rows represent genes ordered by hierarchical cluster analysis. Shading indicates relative expression of each gene with respect to the gene median expression (white equal to, red above, and blue below the median value; gray, missing values as a result of unreliable measurement).
|
| Characteristic | Overall (N = 84) | ERG Expression Quartiles 1-3 (n = 63) | ERG Expression Quartile 4 (n = 21) | P* | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| No. of Patients | % | No. of Patients | % | No. of Patients | % | |||||
| Age, years | ||||||||||
| Median | 47 | 47 | 48 | .616 | ||||||
| Range | 18-59 | 18-59 | 26-59 | |||||||
| Sex, male | 45 | 54 | 35 | 56 | 10 | 48 | .617 | |||
| Race (n = 1 unknown) | .99 | |||||||||
| White | 73 | 88 | 54 | 87 | 19 | 90 | ||||
| Nonwhite | 10 | 12 | 8 | 13 | 2 | 10 | ||||
| FAB (n = 2 unknown) | .023 | |||||||||
| M0/M1 | 19 | 23 | 9 | 15 | 10 | 48 | ||||
| M2 | 27 | 33 | 21 | 34 | 6 | 29 | ||||
| M4 | 22 | 27 | 17 | 28 | 5 | 24 | ||||
| M5 | 11 | 13 | 11 | 18 | 0 | 0 | ||||
| M6 | 1 | 1 | 1 | 2 | 0 | 0 | ||||
| AML, unclassified | 2 | 2 | 2 | 3 | 0 | 0 | ||||
| Hemoglobin, g/dL | ||||||||||
| Median | 8.9 | 9.1 | 8.4 | .470 | ||||||
| Range | 4.6-12.9 | 4.6-12.8 | 7.1-12.9 | |||||||
| Platelets, × 109/L | ||||||||||
| Median | 60.5 | 55 | 64 | .473 | ||||||
| Range | 5-378 | 5-378 | 21-235 | |||||||
| WBC count, × 109/L | ||||||||||
| Median | 22.8 | 19.9 | 24.9 | .824 | ||||||
| Range | 0.8-295.0 | 0.8-295.0 | 1.6-118.4 | |||||||
| Percentage of BM blasts | ||||||||||
| Median | 57 | 53 | 66 | .056 | ||||||
| Range | 28-90 | 28-88 | 28-90 | |||||||
| Percentage of PB blasts | ||||||||||
| Median | 50 | 46.5 | 58 | .045 | ||||||
| Range | 0-97 | 0-97 | 20-95 | |||||||
| FLT3 status | .742 | |||||||||
| FLT3WT/WT | 70 | 83 | 53 | 84 | 17 | 81 | ||||
| FLT3ITD/WT | 14 | 17 | 10 | 16 | 4 | 19 | ||||
| MLL PTD (n = 1 unknown) | .411 | |||||||||
| Yes | 8 | 10 | 5 | 8 | 3 | 14 | ||||
| No | 75 | 90 | 57 | 92 | 18 | 86 | ||||
| BAALC expression† | .042 | |||||||||
| Low | 42 | 50 | 36 | 57 | 6 | 29 | ||||
| High | 42 | 50 | 27 | 43 | 15 | 71 | ||||
| Extramedullary involvement | ||||||||||
| CNS | 0 | 0 | 0 | 0 | 0 | 0 | ||||
| Hepatomegaly | 4 | 5 | 4 | 6 | 0 | 0 | .568 | |||
| Splenomegaly | 5 | 6 | 4 | 6 | 1 | 5 | .99 | |||
| Lymphadenopathy | 8 | 10 | 5 | 8 | 3 | 14 | .406 | |||
| Skin infiltrates | 10 | 12 | 8 | 13 | 2 | 10 | .99 | |||
| Gum hypertrophy | 16 | 19 | 15 | 24 | 1 | 5 | .060 | |||
| Induction regimen | .078 | |||||||||
| ADE | 39 | 46 | 33 | 52 | 6 | 29 | ||||
| ADEP | 45 | 54 | 30 | 48 | 15 | 71 | ||||
Abbreviations: ERG, ETS-related gene; FAB, French-American-British classification; AML, acute myeloid leukemia; BM, bone marrow; PB, peripheral blood; MLL PTD, partial tandem duplication of the MLL gene; FLT3WT/WT, patients with only wild-type FLT3 genes; FLT3ITD/WT patients with internal tandem duplication of the FLT3 gene and the wild-type FLT3 allele; ADE, cytarabine, daunorubicin, and etoposide; ADEP, cytarabine, daunorubicin, etoposide, and valspodar.
*P compares differences in presenting characteristics between patients with the three lowest quartiles and the highest quartile of ERG expression.
†BAALC expression dichotomized at the median value.15
|
| End Point | Overall (N = 84) | ERG Expression Quartiles 1-3 (n = 63) | ERG Expression Quartile 4 (n = 21) | P* |
|---|---|---|---|---|
| CR | ||||
| No. | 68 | 52 | 16 | .532 |
| % | 81 | 83 | 76 | |
| Relapse | ||||
| No. | 30 | 17 | 13 | .001 |
| % | 44 | 33 | 81 | |
| Death in CR | ||||
| No. | 7 | 6 | 1 | .99 |
| % | 10 | 12 | 6 | |
| CIR | ||||
| Median, years | Not reached | Not reached | 0.7 | < .001 |
| CIR at 5 years | ||||
| % | 44 | 33 | 81 | |
| 95% CI | 32 to 56 | 20 to 46 | 60 to 100 | |
| OS | ||||
| Median, years | 3.1 | Not reached | 1.2 | .011 |
| Alive at 5 years | ||||
| % | 43 | 51 | 19 | |
| 95% CI | 32 to 53 | 38 to 62 | 6 to 38 |
Abbreviations: ERG, ETS-related gene; CR, complete remission; CIR, cumulative incidence of relapse; OS, overall survival.
*P compares differences in outcome between patients with the three lowest quartiles and the highest quartile of ERG expression.
|
|
| Gene Symbol | Name | Fold Change | P |
|---|---|---|---|
| HEMGN | Hemogen | 2.69 | .00073 |
| ERG | V-ets erythroblastosis virus E26 oncogene like (avian) | 2.60 | .00039 |
| IKIP | IKK interacting protein | 2.48 | .00049 |
| BCL11A | B-cell CLL/lymphoma 11A (zinc finger protein) | 2.46 | .00002 |
| DAPK1 | Death-associated protein kinase 1 | 2.19 | .00005 |
| GRSP1 | GRP1-binding protein GRSP1 | 2.16 | .00066 |
| GAS5 | Growth arrest–specific 5 | 2.14 | .00003 |
| GUCY1A3 | Guanylate cyclase 1, soluble, alpha 3 | 2.14 | .00032 |
| KLHDC1 | Kelch domain containing 1 | 2.05 | .00083 |
| HIST2H4 | Histone 2, H4 | 2.04 | .00077 |
| ATP6V1C1 | ATPase, H+ transporting, lysosomal 42 kd, V1 subunit C, isoform 1 | 2.03 | .00099 |
| GTF2H2 | General transcription factor IIH | 2.03 | .00002 |
| RAB10 | RAB10, member RAS oncogene family | 2.01 | .00049 |
| ZNF638 | Zinc finger protein 638 | 2.00 | .00040 |
Abbreviations: ERG, ETS-related gene; IKK, I kappa B kinase; CLL, chronic lymphoid leukemia.
Supported by National Cancer Institute (Bethesda, MD) Grants No. CA101140, CA77658, CA102031, CA31946, CA09512, CA16058, and CA90469 and The Coleman Leukemia Research Foundation.
Both G.M. and C.D. Baldus contributed equally to this work.
Authors' disclosures of potential conflicts of interest are found at the end of this article.
We thank Marko I. Klisovic for his excellent technical support.
| 1. | Mrózek K, Heerema NA, Bloomfield CD: Cytogenetics in acute leukemia. Blood Rev 18::115,2004-136, Crossref, Medline, Google Scholar |
| 2. | Grimwade D, Walker H, Oliver F, et al: The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1,612 patients entered into the MRC AML 10 trial. Blood 92::2322,1998-2333, Crossref, Medline, Google Scholar |
| 3. | Slovak ML, Kopecky KJ, Cassileth PA, et al: Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: A Southwest Oncology Group/Eastern Cooperative Oncology Group study. Blood 96::4075,2000-4083, Crossref, Medline, Google Scholar |
| 4. | Byrd JC, Mrózek K, Dodge RK, et al: Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: Results from Cancer and Leukemia Group B (CALGB 8461). Blood 100::4325,2002-4336, Crossref, Medline, Google Scholar |
| 5. | Farag SS, Ruppert AS, Mrózek K, et al: Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: A Cancer and Leukemia Group B study. J Clin Oncol 23::482,2005-493, Link, Google Scholar |
| 6. | Marcucci G, Mrózek K, Bloomfield CD: Molecular heterogeneity and prognostic biomarkers in adults with acute myeloid leukemia and normal cytogenetics. Curr Opin Hematol 12::68,2005-75, Crossref, Medline, Google Scholar |
| 7. | Caligiuri MA, Strout MP, Lawrence D, et al: Rearrangement of () in acute myeloid leukemia with normal cytogenetics. Cancer Res 58::55,1998-59, ALL1 MLL Medline, Google Scholar |
| 8. | Schnittger S, Kinkelin U, Schoch C, et al: Screening for MLL tandem duplication in 387 unselected patients with AML identify a prognostically unfavorable subset of AML. Leukemia 14::796,2000-804, Crossref, Medline, Google Scholar |
| 9. | Döhner K, Tobis K, Ulrich R, et al: Prognostic significance of partial tandem duplications of the MLL gene in adult patients 16 to 60 years old with acute myeloid leukemia and normal cytogenetics: A study of the Acute Myeloid Leukemia Study Group Ulm. J Clin Oncol 20::3254,2002-3261, Link, Google Scholar |
| 10. | Whitman SP, Archer KJ, Feng L, et al: Absence of the wild-type allele predicts poor prognosis in adult acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of : A Cancer and Leukemia Group B study. Cancer Res 61::7233,2001-7239, de novo FLT3 Medline, Google Scholar |
| 11. | Kottaridis PD, Gale RE, Frew ME, et al: The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: Analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 98::1752,2001-1759, Crossref, Medline, Google Scholar |
| 12. | Thiede C, Steudel C, Mohr B, et al: Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: Association with FAB subtypes and identification of subgroups with poor prognosis. Blood 99::4326,2002-4335, Crossref, Medline, Google Scholar |
| 13. | Schnittger S, Schoch C, Dugas M, et al: Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: Correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood 100::59,2002-66, Crossref, Medline, Google Scholar |
| 14. | Fröhling S, Schlenk RF, Breitruck J, et al: Prognostic significance of activating mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: A study of the AML Study Group Ulm. Blood 100::4372,2002-4380, FLT3 Crossref, Medline, Google Scholar |
| 15. | Baldus CD, Tanner SM, Ruppert AS, et al: expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: A Cancer and Leukemia Group B study. Blood 102::1613,2003-1618, BAALC Crossref, Medline, Google Scholar |
| 16. | Baldus CD, Thiede C, Bloomfield CD, et al: High expression as an independent adverse risk factor in 309 patients with acute myeloid leukemia (AML) and normal cytogenetics: Results of the SHG'96 study. Blood 104::554a,2004, (abstr 2009)BAALC Crossref, Google Scholar |
| 17. | Bienz M, Ludwig M, Oppliger Leibundgut E, et al: Risk assessment in patients with acute myeloid leukemia and a normal karyotype. Clin Cancer Res 11::1416,2005-1424, Crossref, Medline, Google Scholar |
| 18. | Fröhling S, Schlenk RF, Stolze I, et al: mutations in younger adults with acute myeloid leukemia and normal cytogenetics: Prognostic relevance and analysis of cooperating mutations. J Clin Oncol 22::624,2004-633, CEBPA Crossref, Medline, Google Scholar |
| 19. | Whitman SP, Liu S, Vukosavljevic T, et al: The partial tandem duplication: Evidence for recessive gain-of-function in acute myeloid leukemia identifies a novel patient subgroup for molecular-targeted therapy. Blood 106::345,2005-352, MLL Crossref, Medline, Google Scholar |
| 20. | Baldus CD, Liyanarachchi S, Mrózek K, et al: Acute myeloid leukemia with complex karyotypes and abnormal chromosome 21: Amplification discloses overexpression of , , and genes. Proc Natl Acad Sci U S A 101::3915,2004-3920, APP ETS2 ERG Crossref, Medline, Google Scholar |
| 21. | Oikawa T: ETS transcription factors: Possible targets for cancer therapy. Cancer Sci 95::626,2004-633, Crossref, Medline, Google Scholar |
| 22. | Oikawa T, Yamada T: Molecular biology of the Ets family of transcription factors. Gene 303::11,2003-34, Crossref, Medline, Google Scholar |
| 23. | McLaughlin F, Ludbrook VJ, Cox J, et al: Combined genomic and antisense analysis reveals that the transcription factor Erg is implicated in endothelial cell differentiation. Blood 98::3332,2001-3339, Crossref, Medline, Google Scholar |
| 24. | Ichikawa H, Shimizu K, Hayashi Y, et al: An RNA-binding protein gene, TLS/FUS, is fused to in human myeloid leukemia with t(16;21) chromosomal translocation. Cancer Res 54::2865,1994-2868, ERG Medline, Google Scholar |
| 25. | Sorensen PHB, Lessnick SL, Lopez-Terrada D, et al: A second Ewing's sarcoma translocation, t(21;22), fuses the EWS gene to another ETS-family transcription factor, ERG. Nat Genet 6::146,1994-151, Crossref, Medline, Google Scholar |
| 26. | Petrovics G, Liu A, Shaheduzzaman S, et al: Frequent overexpression of -related gene-1 () in prostate cancer transcriptome. Oncogene 24::3847,2005-3852, ETS ERG1 Crossref, Medline, Google Scholar |
| 27. | Hart AH, Corrick CM, Tymms MJ, et al: Human is a proto-oncogene with mitogenic and transforming activity. Oncogene 10::1423,1995-1430, ERG Medline, Google Scholar |
| 28. | Kolitz JE, George SL, Dodge RK, et al: Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC- 833 in untreated adults with acute myeloid leukemia younger than 60 years: Final induction results of Cancer and Leukemia Group B Study 9621. J Clin Oncol 22::4290,2004-4301, Link, Google Scholar |
| 29. | Döhner H, Arthur DC, Ball ED, et al: Trisomy 13: A new recurring chromosome abnormality in acute leukemia. Blood 76::1614,1990-1621, Crossref, Medline, Google Scholar |
| 30. | Mitelman F (ed): ISCN (1995): An International System for Human Cytogenetic Nomenclature . Basel, Switzerland, Karger, 1995 Google Scholar |
| 31. | Beillard E, Pallisgaard N, van der Velden VHJ, et al: Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using ‘real-time’ quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR): A Europe Against Cancer program. Leukemia 17::2474,2003-2486, Crossref, Medline, Google Scholar |
| 32. | Gabert J, Beillard E, van der Velden VHJ, et al: Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia: A Europe Against Cancer program. Leukemia 17::2318,2003-2357, Crossref, Medline, Google Scholar |
| 33. | Marcucci G, Caligiuri MA, Döhner H, et al: Quantification of fusion transcript by real-time RT-PCR in patients with INV(16) acute myeloid leukemia. Leukemia 15::1072,2001-1080, CBFbeta/MYH11 Crossref, Medline, Google Scholar |
| 34. | Cheson BD, Cassileth PA, Head DR, et al: Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol 8::813,1990-819, Link, Google Scholar |
| 35. | Gray RJ: A class of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16::1141,1988-1154, Crossref, Google Scholar |
| 36. | Cox DR: Regression models and life tables. J R Stat Soc B 34::187,1972-202, Google Scholar |
| 37. | Fine JP, Gray RJ: A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94::496,1999-509, Crossref, Google Scholar |
| 38. | Li C, Wong W: DNA-chip analyzer (dChip), in Parmigiani G, Garrett ES, Irizarry R, et al (eds): The Analysis of Gene Expression Data: Methods and Software . New York, NY, Springer-Verlag, , pp,2003 120-141 Google Scholar |
| 39. | Schadt EE, Li C, Ellis B, et al: Feature extraction and normalization algorithms for high-density oligonucleotide gene expression array data. J Cell Biochem 37::120,2001-125, (suppl) Google Scholar |
| 40. | Li C, Wong WH: Model-based analysis of oligonucleotide arrays: Expression index computation and outlier detection. Proc Natl Acad Sci U S A 98::31,2001-36, Crossref, Medline, Google Scholar |
| 41. | Satterwhite E, Sonoki T, Willis TG, et al: The gene family: Involvement of in lymphoid malignancies. Blood 98::3413,2001-3420, BCL11 BCL11A Crossref, Medline, Google Scholar |
| 42. | Li CY, Zhan YQ, Xu CW, et al: EDAG regulates the proliferation and differentiation of hematopoietic cells and resists cell apoptosis through the activation of nuclear factor-kappaB. Cell Death Differ 11::1299,2004-1308, Crossref, Medline, Google Scholar |
| 43. | Yang LV, Nicholson RH, Kaplan J, et al: is a novel nuclear factor specifically expressed in mouse hematopoietic development and its human homologue EDAG maps to chromosome 9q22, a region containing breakpoints of hematological neoplasms. Mech Dev 104::105,2001-111, Hemogen Crossref, Medline, Google Scholar |
| 44. | An L-L, Li G, Wu K-F, et al: High expression of EDAG and its significance in AML. Leukemia 19::1499,2005-1502, Crossref, Medline, Google Scholar |
| 45. | Voso MT, Scardocci A, Guidi F, et al: Aberrant methylation of DAP-kinase in therapy-related acute myeloid leukemia and myelodysplastic syndromes. Blood 103::698,2004-700, Crossref, Medline, Google Scholar |
| 46. | Furtado S, Payami H, Lockhart PJ, et al: Profile of families with parkinsonism-predominant spinocerebellar ataxia type 2 (SCA2). Mov Disord 19::622,2004-629, Crossref, Medline, Google Scholar |
| 47. | Wilson HL, Wong ACC, Shaw SR, et al: Molecular characterisation of the 22q13 deletion syndrome supports the role of haploinsufficiency of in the major neurological symptoms. J Med Genet 40::575,2003-584, SHANK3/PROSAP2 Crossref, Medline, Google Scholar |
| 48. | Romio L, Wright V, Price K, et al: OFD1, the gene mutated in oral-facial-digital syndrome type 1, is expressed in the metanephros and in human embryonic renal mesenchymal cells. J Am Soc Nephrol 14::680,2003-689, Crossref, Medline, Google Scholar |
| 49. | Delattre O, Zucman J, Plougastel B, et al: Gene fusion with an DNA-binding domain caused by chromosome translocation in human tumours. Nature 359::162,1992-165, ETS Crossref, Medline, Google Scholar |
| 50. | Urano F, Umezawa A, Hong W, et al: A novel chimera gene between and , encoding the adenovirus E1A enhancer-binding protein, in extraosseous Ewing's sarcoma. Biochem Biophys Res Commun 219::608,1996-612, EWS E1A-F Crossref, Medline, Google Scholar |
| 51. | Jeon I-S, Davis JN, Braun BS, et al: A variant Ewing's sarcoma translocation (7;22) fuses the gene to the gene . Oncogene 10::1229,1995-1234, EWS ETS ETV1 Medline, Google Scholar |
| 52. | de Alava E, Pardo J: Ewing tumor: Tumor biology and clinical applications. Int J Surg Pathol 9::7,2001-17, Crossref, Medline, Google Scholar |
| 53. | Baltzinger M, Mager-Heckel A-M, Remy P: Xl erg: Expression pattern and overexpression during development plead for a role in endothelial cell differentiation. Dev Dyn 216::420,1999-433, Crossref, Medline, Google Scholar |
